Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.

June 30, 2026 updated by: University College, London

Identification of Imaging Biomarkers and Predictive Modelling of Proliferative Vitreoretinopathy Using Deep Learning.

Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).

Study aims to help tailor patients' treatments and improve outcomes by:

[i] studying imaging biomarkers of PVR, and [ii] develop AI models for PVR detection.

Inclusion:

  • Patients with 'complicated' retinal detachment with PVR recruited to a phase 1 dose-finding trial called MORPH-1.
  • Patients with 'simple' retinal detachment without PVR recruited to a PhD study.

Non -invasive multimodal imaging and anonymized imaging will be used to study imaging biomarkers of PVR and develop deep learning models to predict PVR in collaboration with an artificial intelligence (AI) expert team at UCL Institute of Ophthalmology.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

MORPH-1 - PVR detachments Cohort-NHS - primary RRD without PVR requiring PPV with PVD.

Description

Inclusion Criteria:

  • MORPH-1 and Cohort-NHS study imaging

Exclusion Criteria:

  • Participants from above studies who have not consented for image analysis and AI related analysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Rhegmatogenous retinal detachment without proliferative vitreoretinopathy
Rhegmatogenous retinal detachment without proliferative vitreoretinopathy at the time of their primary surgery
Rhegmatogenous retinal detachment with proliferative vitreoretinopathy
Rhegmatogenous retinal detachment with proliferative vitreoretinopathy at the time of their primary surgery or post-operatively with recurrent retinal detachment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To study multimodal imaging biomarkers of PVR.
Time Frame: Preoperative biomarkers of PVR on cases with established PVR Post-operative biomarkers of PVR on cases that develop PVR in the first 3 months.
Use multimodal imaging namely widefield Optos, Widefield OCT, OCT macula, OCT disc, OCT EDI and OCTA to describe biomarkers of PVR.
Preoperative biomarkers of PVR on cases with established PVR Post-operative biomarkers of PVR on cases that develop PVR in the first 3 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To develop deep learning AI models for PVR detection in retinal detachment.
Time Frame: Post-operative 3 months

Use widefield Optos imaging and OCT to:

  • Develop outputs for presence of PVR (binary), and
  • Develop output for prediction of PVR grade.
Post-operative 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University College, London

Investigators

  • Principal Investigator: James Bainbridge, University College, London

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 12, 2026

Primary Completion (Estimated)

October 15, 2027

Study Completion (Estimated)

October 15, 2027

Study Registration Dates

First Submitted

May 5, 2026

First Submitted That Met QC Criteria

June 30, 2026

First Posted (Actual)

July 2, 2026

Study Record Updates

Last Update Posted (Actual)

July 2, 2026

Last Update Submitted That Met QC Criteria

June 30, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EDGE 183954

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Within participant's consent.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Proliferative Vitreoretinopathy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe